ASH 2020 | Real-world data on brentuximab vedotin with chemotherapy in Hodgkin lymphoma
Tycel Phillips
• 14 Dec 2020
Tycel Phillips, MD, University of Michigan, Ann Arbor, MI, presents the results of a retrospective analysis of the characteristics of patients with classical Hodgkin lymphoma receiving brentuximab vedotin with chemotherapy. Treatment with brentuximab vedotin, doxorubicin, vinblastine and dacarbazine (A+AVD) was shown to significantly improve progression-free survival (PFS) in patients with newly diagnosed classical Hodgkin lymphoma when compared to doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) in the Phase III ECHELON-1 study (NCT01712490). Data from 4259 patients was included in the retrospective analysis. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
